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Abstract
The phosphoinositide 3-kinase (PI3K) family has multiple vascular functions, but the specific
regulatory isoform supporting lymphangiogenesis remains unidentified. Here we report that
deletion of the Pik3r1 gene, encoding the regulatory subunits p85α, p55α, and p50α impairs
lymphatic sprouting and maturation, and causes abnormal lymphatic morphology, without major
impact on blood vessels. Pik3r1 deletion had the most severe consequences among gut and
diaphragm lymphatics, which share the retroperitoneal anlage, initially suggesting that the Pik3r1
role in this vasculature is anlage-dependent. However, whereas lymphatic sprouting toward the
diaphragm was arrested, lymphatics invaded the gut, where remodeling and valve formation were
impaired. Thus, cell-origin fails to explain the phenotype. Only the gut showed lymphangiectasia,
lymphatic up-regulation of the TGFβ co-receptor endoglin, and reduced levels of mature VEGF-C
protein. Our data suggest that Pik3r1 isoforms are required for distinct steps of embryonic
lymphangiogenesis in different organ microenvironments, whereas they are largely dispensable for
hemangiogenesis.
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INTRODUCTION
PI3Ks control cell size, metabolism, differentiation, survival, migration, and proliferation
(Engelman et al., 2006; Fruman and Bismuth, 2009). PI3K-mediated pathways are being
pursued as pharmacological targets for halting tumor growth, metastasis, and angiogenesis
(Stephens et al., 2005; Garcia-Echeverria and Sellers, 2008), but drug-specificity remains
challenging due to widespread expression of PI3K proteins. Identifying and targeting
specific subunits may help address those concerns.
There are four subgroups of PI3K enzyme (class Ia, Ib II and III) that differ in their
regulation and substrate selectivity. Growth factor receptors activate primarily the class Ia
subgroup, which are dimeric proteins containing a catalytic subunit (p110α, p110β, or
p110δ) and a regulatory subunit (p85α, p55α, p50α, p85β, or p55γ). The dimers are targeted
to membrane-associated signaling complexes through several protein interaction domains in
the regulatory subunits, and through a Ras-binding domain in the catalytic subunit. Vascular
cells express multiple class Ia catalytic and regulatory isoforms. A reasonable hypothesis is
that different regulatory subunits afford specificity to the multiple (lymph)angiogenic
signaling receptors linked to PI3Ks, including Tie1/Tie2 (Peters et al., 2004), and VEGFR-1,
-2 and -3 (Saharinen et al., 2004). However, no step in lymph vessel development has been
ascribed to a specific PI3K regulatory subunit.
Our previous studies prompted us to investigate the hypothesis that regulatory isoforms
encoded by the Pik3r1gene (p85α/p55α/p50α) have more critical functions in
lymphangiogenesis than in hemangiogenesis. Specifically, we previously showed that
Pik3r1 null mice survive to birth but develop chylous ascites, a hallmark of lymphatic
insufficiency (Fruman et al., 2000). Mice lacking only p85α (p55α/p50α isoforms intact)
(Fruman et al., 1999), p55α/p50α (p85α isoform intact) (Chen et al., 2004), or p85β encoded
by Pik3r2 (Ueki et al., 2002) showed no lymphatic defects. However, chylous ascites was
also reported in newborn mice with a point mutation abrogating the interaction between
p110α and Ras (Gupta et al., 2007), implicating p110α as an important Ras effector in
perinatal lymphatic development. Here we report that the class Ia regulatory isoforms
encoded by Pik3r1 are required for organ-specific steps of lymphangiogenesis.
RESULTS AND DISCUSSION
We sought to determine if abnormal lymphatic development underlies chylous ascites
(Fruman et al., 2000) and intestinal edema (Figures 1A,B) in Pik3r1 null mice as follows:
Using LYVE1 (Schledzewski et al., 2006), VEGFR-3 (Lymboussaki et al., 1998) and Prox1
(Rodriguez-Niedenfuhr et al., 2001) as lymphatic endothelial cell markers (Kim et al.,
2007), we analyzed lymphatic density and morphology in Pik3r1-targeted newborns, all of
which presented with chylous ascites (Supplemental Figure s.1). To visualize the complete
vascular tree, we used the pan-endothelial markers VEGFR-2 and PECAM1, whose
expression did not change upon Pik3r1 deletion (data not shown). As shown by LYVE1
whole mount immunohistochemistry (IHC), there was a paucity of serosal lymphatics at
birth in Pik3r1 null mice (Figure 1C,D), as determined by the mean number of vessel branch
points/area (n=5/group; wild-type 11.6 versus null 3.8, p<1×10−5). In contrast, the
lymphatic capillaries (lacteals, (Papp et al., 1962)) were normal in number and size (Figure
1H, (Kim et al., 2007)). The morphology of the remaining Pik3r1 null mesenteric and
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serosal lymphatics was abnormal (Figures 1E–G). Confocal microscopy indicated that
segments of the mesenteric collectors of Pik3r1 null mice were more variable than wild-
type; i.e., some were twice as wide as those of wild-type littermates (Figures 1I,J) and others
were less than half the normal size (Figures 1E,F). Wider distribution of diameter classes in
null versus wild-type lymphatics resulted in a failure to achieve statistical significance for
mean diameter (data not shown). Hemangiogenesis appeared normal except that the
duodenal arcades exhibited additional branching as visualized by alpha smooth muscle actin
(SMA) staining (Figures 1K,L).
Overall, the phenotype of the Pik3r1-targeted newborns was reminiscent of intestinal
lymphangiectasia, a clinical condition in which inflammation or obstructing tumors
(Kolbjornsen et al., 1994) results in poor lymphatic drainage. Our data suggest that in the
absence of Pik3r1, lymphangiectasia resulted from abnormal lymphatic development. Liver
and heart necrosis (Fruman et al., 2000) may also contribute to impaired lymphatic function
in Pik3r1 null mice by impairing venous function, though widespread venous insufficiency
is unlikely because: (i) the newborns lacked pleural effusions (Figures 2A–F) and (ii),
despite significantly decreased dermal lymphatic branching and increased diameter (Figure
2G), subcutaneous edema was barely detectable. Interestingly, Angiopoietin2 null newborn
mice have chylous ascites, but also show pleural effusions, subcutaneous edema, with fewer
and smaller lacteals than control littermates, thus their lymphatic defects differ significantly
from Pik3r1 null mice (Gale et al., 2002). Because angiopoietins signal via PI3K (Peters et
al., 2004), it is still possible that aspects of the Pik3r1 null phenotype reflect a defect in this
pathway. Post-natal blood vessel remodeling is also defective in Angiopoietin2 null mice
(Gale et al., 2002), but this could not be studied in Pik3r1 null mice because they died by
post natal day one. However, Pik3r1 null newborn mice had normal blood vessel density
and morphology, exemplified by whole mount-IHC for SMA in ventral skin (Figures 2H,I),
with the exception of the additional branching of the arcades noted already (Figures 1K,L).
Interestingly, lymphatics from the abdominal surface were significantly reduced (Figures
3A–D, and 3G), but were present in the thoracic surface (Figures 3E,F and 3G), appearing
capable of extending from the body wall but not from the retroperitoneal sac (Oliver, 2004).
These results are consistent with Pik3r1 having different roles on lymph and blood vessel
development, suggesting that Pik3r1 isoforms are required for proper lymphatic patterning
but are dispensable for, or to some extent inhibitory of, blood vessel branching.
To gain insight into the cellular basis for the organ-specific dependency of
lymphangiogenesis, we first questioned whether Pik3r1 loss causes vessel regression, or
arrests vessel growth during development. Seminal work by Sabin ((Sabin, 1913), for a
review see Oliver (Oliver, 2004)) indicates that lymphatics from the gut and abdominal
diaphragm surface originate from the retroperitoneal/mesenteric lymph sac after E14. In
turn, dermal lymphatics extend from paired jugular lymph sacs (after E10.5), a process
halted in Prox1 (Oliver, 2004) and Vegfc (Karkkainen et al., 2004) null mice. By staining
E10.5 to E19.5 embryos, we disproved the hypothesis that impaired anlagen development
explains the organ-specific phenotype because we observed no early differences in timing,
position, and expansion of lymph sacs between Pik3r1 null mice and wild-type littermates
(data not shown). Instead, we found defects at later stages. Specifically, diaphragm invasion
by lymphatics sprouting from the retroperitoneal lymph sac stopped at the central tendon
(Figures 4E–H). In the gut, sprouts reached some microenvironments (mesentery; Figures
4A–D, Figure 5) but were reduced in others (serosa; Figures 5A–D). Moreover, our data
suggest that lymphatic remodeling was dysregulated by Pik3r1 deletion: E16 Pik3r1 null
mice established normal primitive mesenteric vascular plexi (Figures 5A–D) that failed to
mature into the normal network of wild-type littermates in later stage E18.5 embryos.
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Indeed, even before suckling, which stimulates lymphatic transport, mesenteric lymphatics
acquired abnormal constrictions and dilations (Figures 5E–J).
Pharmacological inhibitors of PI3K activity and PI3K mutants decrease endothelial cell
proliferation and survival in vitro (Makinen et al., 2001; Wang et al., 2004). However, loss
of Pik3r1 alone is not always sufficient to impair proliferation; for example, in T cells,
Pik3r2 (p85β) compensates (Deane et al., 2007). Indeed, mesenteric lymphatics of Pik3r1
null mice and wild-type embryos did not differ in proliferation or cell death, as assessed by
BrdU-incorporation and phosphohistone-H3 analyses, or by TUNEL staining, respectively
(data not shown). Instead, our results are consistent with mouse lymphatic development
studies (Kim et al., 2007) that support a vessel-branching mechanism driving mesenteric
plexi remodeling without changes in cell number (Patan, 2004). Alternatively, Pik3r1 null
mice may lack a subpopulation of lymphatic progenitors, like those detected in quail-mouse
chimeras (Pudliszewski and Pardanaud, 2005). Although descriptions of (lymph)angiogenic
mechanisms in the diaphragm are lacking, decreased invasion was the most visible defect in
Pik3r1 null diaphragms. Collectively, these results suggest that Pik3r1 is required for
distinct steps of lymphangiogenesis in distinct organ microenvironments, despite common
vessel origins.
VEGF-C is needed for embryonic lymphangiogenesis (Karkkainen et al., 2004), and its
tumor expression is PI3K-dependent (Tang et al., 2003). Interestingly, we found only
decreased levels of mature ΔNΔC-VEGF-C in the Pik3r1 null gut, without obvious
differences in the levels of precursor pro-VEGF-C, which is the substrate for N-terminal and
C-terminal cleavages by plasmin, furin, and proconvertases (Figure 6A, (Jeltsch et al.,
2003)). Interpreting these results will require a better understanding of post-translational
processing of VEGF-C in vivo, and of the role of the different products, which signal
through different VEGFRs in lymph vessel growth, remodeling, and maturation (Jeltsch et
al., 2003).
To better understand the impact of Pik3r1 deletion on maturation, we assessed smooth
muscle/pericyte investment and valve formation. Mesenteric lymphatics of Pik3r1 null mice
lacked valves (Figures 6B–E); instead of endothelial lumenal flaps, we found abnormal
vessel-wall constrictions (Figures 1–5, 6B,D). Only two other mutants show valve-less
phenotypes: the knockout of Foxc2 (a member of the forkhead family of transcription
factors, (Petrova et al., 2004)), and the knock-in of a PDZ-less ephrinB2 mutant (Makinen et
al., 2005). Although Eph-receptors may signal via PI3K (Makinen et al., 2005), it is not
understood how ephrinB2 affects valve formation.
Previous data indicate that Foxc2 ablation causes lymph valve agenesis and abnormal
pericyte/SMC investment, due to up-regulation of Pdgfb and endoglin transcription in
lymphatics (Petrova et al., 2004). Therefore, to test the hypothesis that PI3K regulates
endoglin transcription, luciferase reporter assays were conducted on cultured human primary
lymphatic endothelial cells transfected using human-derived endoglin promoter-luciferase
constructs (Rius et al., 1998; Botella et al., 2002). First, a series of endoglin promoter
deletion mutations comprising sequential human 5′ non-coding promoter regions extending
from the minimal promoter (Figure 7A, base pairs -148–281, relative to the endoglin
transcription start site) to a position 782 base pairs upstream of the transcription start site
(Figure 7A, 782–281) were cotransfected with either the wild-type or dominant-negative
p85α expression construct. These constructs were characterized elsewhere (Rius et al., 1998;
Botella et al., 2002). Analysis of the endoglin promoter deletion mutations indicated that
PI3K-mediated repression of endoglin expression is governed at least in part by elements
contained in the proximal promoter DNA segment 5′ to position -281, relative to the
transcription initiation site in the minimal endoglin promoter (Figure 7A). Moreover,
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cotransfection of the wild-type p85α subunit expression inhibited the shortest maximally-
responsive endoglin luciferase reporter construct (−397/+281, Figure 7B) in a dose-
dependent fashion. In contrast, the dominant-negative construct, p85αdn, was significantly
less effective in terms of inhibition of endoglin promoter reporter expression (Figure 7B).
A limitation of this approach is that the efficiency of transfection of the primary human
lymphatic endothelial cells with p85 constructs, while sufficient for the reporter assays, was
not sufficient to produce a statistically significant change in endogenous endoglin protein
levels overall, as determined by western blotting. However, consistent with the reporter data
shown, luciferase reporter experiments using constitutively active forms of the PI3K p110
catalytic subunit and constitutively active Akt, but not dominant-negative forms of these
proteins, showed increasing inhibition of the endoglin promoter with plasmid dosage (data
not shown). Overexpression of wild-type p85α may exhibit a dominant-negative effect due
to overproduction of p85α monomers, which could compete with endogenous p85/p110
dimers. Thus, in in vitro systems, p85α overexpression could produce a similar effect as the
p85α dominant negative mutant that lacks any ability to bind p110. Our results suggest that
this does not occur in this system, but are consistent with loss of repression of endoglin
expression in Pik3r1 null lymphatics, providing support for the view that endoglin
expression is inhibited by PI3K at the transcriptional level, and suggesting that the
regulation of endoglin by PI3K in mice is recapitulated in human lymphatic endothelial
cells. To further test the hypothesis that PI3K regulates endoglin expression in developing
lymphatics, we prepared whole mount sections, which were immunostained with anti-
endoglin antibody. Consistent with the preceding results, we found increased endoglin
expression in gut lymphatics of Pik3r1 null mice (Figures 7C-7F).
Valve formation is either independently controlled by Foxc2 and Pik3r1, or Pik3r1 acts
downstream of Foxc2. However, in contrast to Foxc2 null mice, Pik3r1 ablation was not
accompanied by increased mural cell recruitment, as assessed with IHC for SMA (Figures
1–5) and NG2 (data not shown). Foxc2 expression in adipocytes is p85/PI3K-dependent
(Gronning et al., 2002), and so is the subcellular localization and phosphorylation status of
other forkhead superfamily members (Abid et al., 2004). However, we found no difference
in Foxc2 between Pik3r1 null mice and wild-type littermates by immunohistochemistry and
western blot analyses (data not shown). Our data suggest that Pik3r1 isoforms are
dispensable for proper mural cell investment, but are necessary for lymph valve formation.
Endoglin has been implicated in blood vessel maturation and stability. Mutations in endoglin
are responsible for hereditary hemorrhagic telangiectasia (McAllister et al., 1994), which is
caused by reduced levels of endoglin protein expression ((Pece-Barbara et al., 1999),
reviewed in (Bernabeu et al., 2007)). Recent studies using endoglin transgenic mice indicate
that endoglin overexpression in vascular precursor cells promotes vascular smooth muscle
cell investment of major vessels (Mancini et al., 2007). The finding that endoglin, a
prohemangiogenic endothelial cell marker, is upregulated in Pik3r1 null mouse lymphatic
tissues and human lymphatic endothelial cells suggests that PI3K-dependent endoglin
repression opposes angiogenesis and plays a role in lymphangiogenic vessel identity.
These data not only suggest a mechanism whereby abnormal endoglin expression in Pik3r1
null lymphatic vessels contributes to the pathology observed in Pik3r1 null mice, but also
provide the novel insight that PI3K-dependent regulation of endoglin may play a role in
lymph vessel homeostasis. Endoglin expression is thought to repress TGFβ signaling by
inhibiting the TGFβ receptor ALK5 (Lastres et al., 1996; Blanco et al., 2005).
Pharmacologic inhibition of ALK5-dependent TGFβ signaling in lymphatic cells accelerates
lymphangiogenesis in a mouse model of chronic peritonitis (Oka et al., 2008). Thus, our
study suggests that endoglin may play a role in regulating lymphangiogenic homeostasis.
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This view is supported by the observation that endoglin is absent in normal blood vascular
smooth muscle, but is increased following vessel injury (Ma et al., 2000) and in
atherosclerotic vascular smooth muscle (Conley et al., 2000).
The present study, combined with the absence of lymphatic defects in p85α null (p55α/p50α
isoforms intact) and p55α/p50α null (p85α isoform intact) embryos, indicates that p85α/
p55α/p50α isoforms have redundant but required functions in lymphatic development. These
functions are most likely to involve phosphotyrosine-based associations with Tie1/Tie2,
PDGFRs, VEGFRs, or Eph receptors, because what is preserved among the Pik3r1 isoforms
are the SH2 domains. Based on the lymphatic defects of p110α-mutant mice (Gupta et al.,
2007), an attractive model is that effective activation of class Ia PI3K requires at least two
interactions downstream of receptor tyrosine kinases: SH2 domains of a regulatory isoform
binding to phosphotyrosine, and binding of p110α to activated Ras. Further in vitro and in
vivo studies to determine the lymphangiogenic signaling pathway(s) dependent on each
isoform, and to elucidate the extent to which their function in vascular development is
endothelial cell-autonomous will provide new insight into the mechanism of
lymphangiogenesis.
METHODS
Protocols were pre-approved by our Institutional Animal Care and Use Committee. We
followed published methods for generation of the Pik3r-targeted mice (Fruman et al., 2000),
western blot analysis (Fruman et al., 2000), whole mount immunohistochemistry (IHC)
(Karkkainen et al., 2004; Petrova et al., 2004), lymphatic endothelial cell culture (Petrova et
al., 2004), and luciferase reporter analyses (Rius et al., 1998; Botella et al., 2002). At least
eight surviving mice of each genotype were analyzed per data point.
Image analysis of lymphatic vessel branching and diameter was estimated using a
morphometric approach (Kumar et al., 1997). For vessel branching, the number of branch
points was determined for a minimum of five independent samples each from wild-type and
null mouse specimens. For vessel diameters, the width of the vessel lumen was obtained by
delineating the lumenal diameter, in triplicate, using Photoshop CS2 (Adobe Systems).
Statistical significance was assessed using a two-tailed Student’s t-Test and assuming
unequal variances.
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Figure 1. Intestinal lymphatic defects in Pik3r1 null newborns
(A,B): Gross anatomy of a wild-type (+/+) and Pik3r1 (−/−) null newborn littermates.
Chylous ascites was evident in the intact peritoneum of Pik3r1 null mice (Supplemental
Data). Intestinal edema (white arrow), and liver necrosis (black arrows) are indicated in the
Pik3r1 null organs. (C–F): Intestinal lymphatics stained by whole mount
immunofluorescence for LYVE1 (C,D), VEGFR3 (green, E,F), and SMA (orange, that
bleeds through the green channel (E,F)). The white arrow in panel D highlights the lack of
intestinal lymphatics. (E,F): The white arrows indicate segments of the mesenteric collectors
highlighting the difference in lymph vessel diameter and morphology; the red arrow in panel
E highlights a lymphatic valve of the sort lacking in the null mouse specimens.
(G,H): Intestinal lymphatics LYVE1-stained by whole mount immunoperoxidase method.
LYVE1+ presumptive macrophages in the mesentery (Kim et al., 2007; Kubota et al., 2009)
are marked with asterisks. (H): Brown-stained lymphatic vessels (lacteals) inside the villi are
indicated with white arrows. (I,J): Confocal immunofluorescence for VEGFR3 (green) and
SMA (red). The white arrows highlight the increased diameter of the lymphatic collectors of
Pik3r1 null (J) compared to wild-type mice (I). (K,L): Whole mount immunofluorescence of
newborn small intestine stained for SMA. Blood vessels are highlighted by this method
because they have higher numbers of smooth muscle cells (arteries>veins⋙lymphatics).
Increased blood vessel branching (arrows, panel K versus L) at the level of the arcades is
visible within the white boxes. Scale bars are as indicated in the panels.
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Figure 2. Dermal lymphatic defects in Pik3r1 null newborns
Lymphatics (A–F) and blood vessels (H,I) from the ventral skin of a wild-type and a Pik3r1
null newborn littermate, stained whole mount for VEGFR3 (green) and SMA (red). The
central hole (B,E) is the umbilicus. The asterisks mark the ventral midline (D). (G):
Quantitative image analysis of wild-type and Pik3r null lymphatic mean branch point count
and diameter. Asterisks mark significantly different values with the associated Student’s T-
test p values indicated below the figure.
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Figure 3. Abdominal lymphatic defects in Pik3r1 null newborns
(A–F): Diaphragm lymphatics and blood vessels of a representative Pik3r1 null newborn
and a wild-type littermate, stained whole mount for VEGFR3 (green) and SMA (red),
respectively. In contrast to the abdominal surface of the diaphragm (A–D), the thoracic
surface contained a lymphatic network in both wild-type and Pik3r1 null mice (E,F). (G):
Quantitative image analysis of wild-type and Pik3r1 null mouse lymphatic vessel mean
branch point count per constant area.
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Figure 4. Arrested diaphragm invasion underlies lymphangiogenesis abnormalities in Pik3r1 null
embryos
(A–H): E18 embryos stained whole mount with antibodies to detect LYVE1, VEGFR3, and
SMA. (A–D): LYVE1 whole mount mesenterics stained using HRP substrate DAB. (E–H):
Diaphragm lymphatics expanding past the central tendon into the pleuro-peritoneal
membrane at E18 in wild-type but not in a null Pik3r1 littermate embryo, as visualized by
whole mount double-immunofluorescence for LYVE1 and VEGFR3. The asterisk indicates
a segment of attached liver.
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Figure 5. Inappropriate gut remodeling contributes to the lymphangiogenesis abnormalities in
Pik3r1 null embryos
Mesenteric lymphatics of wild-type and Pik3r1 null littermate mice at E16 (A–D), E18.5
(E–J). (E–G, I): Lymphatic vessels are indicated by white arrows; white asterisks (E,F) mark
LYVE1+ macrophages (Kim et al., 2007). Art, artery; LV, lymphatic vessel.
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Figure 6. Decreased VEGF-C levels are associated with altered lymphatic wall and valve
structure
(A): p85α and VEGF-C protein levels in western blots of homogenates prepared from
newborn mesenteries and diaphragm crura (three mice were pooled per lane). β-actin was
used as a total protein loading control. (B–E): Whole mount staining for lymphatic
endothelial cell VEGFR3 (green) and mural cell SMA (red). Red arrowheads point to lymph
valves in mesenteric collectors of a wild-type newborn and the corresponding region in a
Pik3r1-null, which display an abnormal wall structure instead of a valve. The white
arrowhead indicates the normal direction of lymph flow.
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Figure 7. Increased lymphatic endothelial endoglin expression in the mesentery of Pik3r1 null
mice
(A,B): Endoglin promoter luciferase constructs were tested in primary human lymphatic
endothelial cell culture for regulation by p85α. (A): Successive endoglin promoter 5′
deletion constructs were transfected along with p85α protein expression construct
corresponding to maximal endoglin promoter inhibition (300 ng/ml). The endoglin promoter
segment numbers represent base pairs numbered from the 5′ terminus to the transcriptional
start site. (B): Lymphatic endothelial cell cultures were transfected with the 397/281
endoglin promoter luciferase construct and either wild-type or dominant-negative p85αdn
protein expression constructs. Histogram black bars, wild- type p85α gray bars, dominant
negative p85α, p85αdn. For expression plasmid dosage studies, empty pcDNA was used to
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maintain constant total DNA levels. (C–F): Anti-endoglin whole mount staining of E19
mesenteries from a Pik3r1 null mouse and a wild-type littermate. Black arrows highlight the
increased endoglin protein expression within the abnormal lymphatic collectors of Pik3r1
null mice.
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